Table 15, Summary of included studies. Comparison 14. Increasing the dose of SSRI versus augmenting with antipsychotic - Further-line treatment

Warning: The NCBI web site requires JavaScript to function. more...

Study	Population	Intervention	Comparison	Details of inadequate response/treatment resistance	Comments
Rocca 2002b RCT Italy	N=60 Mean age (years): 40.8 Gender (% female): 68 Ethnicity (% BME): NR Baseline severity: HAMD 18.3 (more severe)	Paroxetine (dose increase) 40mg/day	Amisulpride 50mg/day + paroxetine 20mg/day	Inadequate response to 3-month treatment with paroxetine 20 mg/day	Treatment length (weeks): 13 Outcomes: Depression symptomatology endpoint Depression symptomatology change score Remission Response Discontinuation due to any reason Discontinuation due to side effects Functional remission Global functioning endpoint

Study

Population

Intervention

Comparison

Details of inadequate response/treatment resistance

Comments

RCT

Italy

N=60

Mean age (years): 40.8

Gender (% female): 68

Ethnicity (% BME): NR

Baseline severity: HAMD 18.3 (more severe)

Paroxetine (dose increase) 40mg/day

Amisulpride 50mg/day + paroxetine 20mg/day

Inadequate response to 3-month treatment with paroxetine 20 mg/day

Treatment length (weeks): 13

Outcomes:

: BME: black and minority ethnic; HAMD: Hamilton depression scale; NR: not reported; RCT: randomised controlled trial; SSRI: selective serotonin reuptake inhibitor

Further-line treatment: Depression in adults: Evidence review D.

NICE Guideline, No. 222.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.